{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T04:37:12Z","timestamp":1649133432690},"reference-count":98,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2020,11,16]]},"DOI":"10.1080\/00325481.2020.1784562","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T20:54:29Z","timestamp":1592600069000},"page":"667-675","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin"],"prefix":"10.1080","volume":"132","author":[{"given":"Craig J.","family":"Currie","sequence":"first","affiliation":[{"name":"Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK"},{"name":"Global Epidemiology, Pharmatelligence, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,7,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"cit0002","unstructured":"National Institute for Care and Clinical Excellence. Type 2 diabetes in adults: management. [cited 2017 Mar 28]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/1-recommendations#individualised-care"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13332"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12260"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02503.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12354"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078118"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12821"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12302"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03040.x"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0985"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13039"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310799"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-04-0251"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61662-0"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61664-4"},{"key":"cit0023","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH). Guidance for clinical trial sponsors establishment and operation of clinical trial data monitoring committees. 2006. [cited 2015 Jan 30]. Available from: http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/ucm127073.pdf."},{"key":"cit0024","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on data monitoring committees. 2005. [cited 2015 Jan 30]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003635.pdf."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1119"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2304"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.09.011"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.12.007"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(96)00131-6"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03181.x"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055807"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.539601"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509105223"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1177\/1740774507087972"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.065"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1351"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.120145"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2006.02.002"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.10.009"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1186\/CVM-2-4-187"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.12.005"},{"issue":"273","key":"cit0042","first-page":"e1","volume":"165","author":"Smith SW","year":"2013","journal-title":"Am Heart J"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314078"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366"},{"key":"cit0045","unstructured":"Center for Drug Evaluation and Research. Application number: 125469Orig1s000. Risk assessment and risk mitigation review(s). [cited 2015 Feb 3]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000RiskR.pdf."},{"key":"cit0046","unstructured":"U.S. Food and Drugs Administration. Drug approval package. Trulicity (dulaglutide) injection. 2014. [cited 2015 Feb 4]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000TOC.cfm"},{"key":"cit0047","unstructured":"U.S. Food and Drugs Administration. FDA Briefing Document. NDA 206321. Liraglutide injection, 3mg. 2014. [cited 2015 Feb 4]. Available from: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm413317.pdf"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.2.298"},{"key":"cit0049","unstructured":"U.S. Food and Drugs Administration. Drugs approval package. Byetta (Exenatide) Injection. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_ByettaTOC.cfm"},{"key":"cit0050","unstructured":"U.S. Food and Drugs Administration. Drug Approval Package. Victoza (Liraglutide [rDNA]) Injection. 2010. [cited 2015 Feb 5]. Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022341s000TOC.cfm"},{"key":"cit0051","unstructured":"U.S. Food and Drug Administration. Drug approval package. Tradjenta (linagliptin) tablets. 2011. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/201280Orig1s000TOC.cfm"},{"key":"cit0052","unstructured":"U.S. Food and Drugs Administration. Drug Approval Package. Onglyza (saxagliptin) Tablets. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022350s000TOC.cfm"},{"key":"cit0053","unstructured":"U.S. Food and Drug Administration. Drug approval package. Januvia (Sitagliptin Phosphate) Tablets. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021995s000TOC.cfm"},{"key":"cit0054","unstructured":"U.S. Food and Drug Administration. Drug approval package. Nesina (alogliptin) tablets. 2014. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/022271Orig1s000TOC.cfm"},{"key":"cit0055","unstructured":"U.S. Food and Drugs Administration. Drug approval package. Linagliptin and metformin tablets (2.5 mg\/500 mg, 2.5 mg\/850 mg and 2.5 mg\/1000 mg). 2013. [cited 2015 Feb 5]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/201281_linagliptin_toc.cfm"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3680"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61112-9"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0953"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.2337\/dci16-0043"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61969-3"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1278"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908359"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.031"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3473-8"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1577"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2012.01.003"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2860-x"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068008"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.07.017"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109501"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.09.070"},{"key":"cit0072","doi-asserted-by":"crossref","unstructured":"Currie CJ, Holden SE, Jenkins\u2010Jones S, et al. Impact of differing glucose\u2010 lowering regimens on the pattern of association between glucose control and survival. Diabetes Obes Metab. 2018;20:821\u2013830.","DOI":"10.1111\/dom.13155"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4169"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1007\/BF01219790"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01469.x"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70027-5"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12349"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.04.013"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1191955"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2017.09.001"},{"key":"cit0082","first-page":"907","volume-title":"Joslin\u2019s Diabetes Mellitus","author":"Krall LP","year":"1985","edition":"12"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30316-3"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.03.048"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12889"},{"key":"cit0086","first-page":"1","author":"Mamza J","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3696-4"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01552.x"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1440-6"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1313"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0508-7"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"cit0094","unstructured":"Supplementary appendix to the ORIGIN Trial. [cited 31 May 2021]. Available from: https:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1203858\/suppl_file\/nejmoa1203858_appendix.pdf"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4422-0"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0622-7"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317729252"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153594"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1784562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T17:13:21Z","timestamp":1620580401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1784562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,12]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11,16]]}},"alternative-id":["10.1080\/00325481.2020.1784562"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1784562","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}